Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In 2008, Roche acquired Genentech, ending the most successful symbiotic business relationship the biotech/pharma sector has ever seen. Morphing biotech business models, pharma management's short-termism and dwindling investor patience means we'll never see the like of it again.
Even if a GM crop can surmount Europe's excessive product registration process, any farmer hoping to plant it must then navigate tortuous, arbitrary and scientifically unjustifiable coexistence regulations.
Clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are surplus to requirements and may even be a barrier for the development of biosimilars of more complicated biologics.
